EyePoint Pharmaceuticals Inc (EYPT)
16.95
-0.70
(-3.97%)
USD |
NASDAQ |
Apr 22, 16:00
18.19
+1.24
(+7.32%)
Pre-Market: 08:55
EyePoint Pharmaceuticals Cash from Investing (TTM): -3.315M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -3.315M |
| September 30, 2023 | 76.75M |
| June 30, 2023 | 84.74M |
| March 31, 2023 | 71.26M |
| December 31, 2022 | -17.26M |
| September 30, 2022 | -83.15M |
| June 30, 2022 | -89.55M |
| March 31, 2022 | -89.56M |
| December 31, 2021 | -33.12M |
| September 30, 2021 | -0.348M |
| June 30, 2021 | -0.345M |
| March 31, 2021 | -0.346M |
| December 31, 2020 | -0.362M |
| September 30, 2020 | -0.176M |
| June 30, 2020 | -0.048M |
| March 31, 2020 | -0.047M |
| December 31, 2019 | -0.213M |
| September 30, 2019 | -0.316M |
| June 30, 2019 | -2.069M |
| March 31, 2019 | -17.12M |
| September 30, 2018 | -16.93M |
| June 30, 2018 | -16.89M |
| March 31, 2018 | -12.76M |
| December 31, 2017 | 5.645M |
| September 30, 2017 | 8.033M |
| Date | Value |
|---|---|
| June 30, 2017 | 13.58M |
| March 31, 2017 | 5.882M |
| December 31, 2016 | 3.98M |
| September 30, 2016 | 1.564M |
| June 30, 2016 | -4.462M |
| March 31, 2016 | -0.026M |
| December 31, 2015 | -4.242M |
| September 30, 2015 | -7.272M |
| June 30, 2015 | -6.733M |
| March 31, 2015 | -6.269M |
| December 31, 2014 | -5.75M |
| September 30, 2014 | -1.383M |
| June 30, 2014 | 0.066M |
| March 31, 2014 | 2.768M |
| December 31, 2013 | 5.592M |
| September 30, 2013 | 7.153M |
| June 30, 2013 | 6.358M |
| March 31, 2013 | 4.168M |
| December 31, 2012 | 3.716M |
| September 30, 2012 | 1.805M |
| June 30, 2012 | 0.606M |
| March 31, 2012 | -1.091M |
| December 31, 2011 | -3.754M |
| September 30, 2011 | -6.875M |
| June 30, 2011 | -9.498M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-89.56M
Minimum
Mar 2022
84.74M
Maximum
Jun 2023
-4.604M
Average
-0.346M
Median
Mar 2021
Cash from Investing (TTM) Benchmarks
| INVO Bioscience Inc | -2.495M |
| Bio-Path Holdings Inc | -- |
| Ocular Therapeutix Inc | -6.087M |
| Aileron Therapeutics Inc | 16.20M |
| Apellis Pharmaceuticals Inc | -0.674M |